巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Ocuphire Pharma

OCUP
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Ocuphire Pharma - 延遲價格・最後更新於 14/01 12:15
最高位
3.700
最低位
3.540
開市價
--
前收市價
3.530
成交量(千)
2.15
成交額(百萬)
0.06
買入
--
賣出
--
每手股數
--
市值(百萬)
69.16
市盈率
--
息率
--
差價
--
52週高低
13.812 - 3.190
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Ocuphire Pharma
證券代碼
OCUP.US
所屬板塊
Biotechnology
公司業務
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
發行量
17300481
公司總部
37000 Grand River Avenue, Suite 120
公司網址
https://www.ocuphire.com
公司電話
+1 248 681-9815
暫無內容

關於

Ocuphire Pharma(OCUP.US)所屬的行業板塊為Biotechnology。
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
詳細公司背景可參考: https://www.ocuphire.com